TScan Therapeutics, Inc.
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
TCRX | US
Overview
Corporate Details
- ISIN(s):
- US89854M1018
- LEI:
- Country:
- United States of America
- Address:
- 830 WINTER STREET, 2451 WALTHAM
- Website:
- https://www.tscan.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing T-cell receptor (TCR) engineered T-cell therapies (TCR-T) for the treatment of cancer. The company's core approach involves identifying highly effective, naturally occurring TCRs and using them to genetically reprogram patient T-cells to recognize and combat cancer. TScan's platform focuses on creating therapies for both hematologic malignancies and solid tumors, aiming to harness the power of the human immune system to deliver safe and effective treatments for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all TScan Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for TScan Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for TScan Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
